Dr. Mark Siegel, M.D

NPI: 1013981380
Total Payments
$2,468
2023 Payments
$131.00
Companies
7
Transactions
21

Payment Breakdown by Category

Food & Beverage$2,468 (100.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $2,468 21 100.0%

Top Paying Companies

Company Total Records Latest Year
Merck Sharp & Dohme Corporation $649.79 7 $0 (2021)
Gilead Sciences, Inc. $612.88 5 $0 (2019)
AbbVie, Inc. $530.11 4 $0 (2019)
QOL Medical, LLC $299.99 2 $0 (2021)
E.R. Squibb & Sons, L.L.C. $131.00 1 $0 (2023)
GlaxoSmithKline, LLC. $123.95 1 $0 (2018)
ALCRESTA THERAPEUTICS, INC. $119.93 1 $0 (2021)

Payment History by Year

Year Amount Transactions Top Company
2023 $131.00 1 E.R. Squibb & Sons, L.L.C. ($131.00)
2021 $438.07 4 QOL Medical, LLC ($299.99)
2020 $125.00 1 Merck Sharp & Dohme Corporation ($125.00)
2019 $895.72 8 AbbVie, Inc. ($395.31)
2018 $495.04 4 Gilead Sciences, Inc. ($249.98)
2017 $382.82 3 AbbVie, Inc. ($134.80)

All Payment Transactions

21 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
05/15/2023 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $131.00 General
Category: Neuroscience
10/21/2021 ALCRESTA THERAPEUTICS, INC. RELIZORB (Device) Food and Beverage In-kind items and services $119.93 General
Category: GASTROENTEROLOGY
09/21/2021 QOL Medical, LLC SUCRAID (Drug) Food and Beverage In-kind items and services $175.00 General
Category: THERAPY FOR CSID
06/29/2021 QOL Medical, LLC SUCRAID (Drug) Food and Beverage In-kind items and services $124.99 General
Category: THERAPY FOR CSID
02/23/2021 Merck Sharp & Dohme Corporation DIFICID (Drug), RECARBRIO, ZINPLAVA Food and Beverage In-kind items and services $18.15 General
Category: INFECTIOUS DISEASE
03/04/2020 Merck Sharp & Dohme Corporation ZINPLAVA (Biological) Food and Beverage In-kind items and services $125.00 General
Category: INFECTIOUS DISEASE
06/12/2019 Merck Sharp & Dohme Corporation DIFICID (Drug), ZINPLAVA Food and Beverage In-kind items and services $124.76 General
Category: INFECTIOUS DISEASE
05/30/2019 AbbVie, Inc. Mavyret (Drug) Food and Beverage In-kind items and services $133.13 General
Category: Virology
04/22/2019 Gilead Sciences, Inc. Epclusa (Drug) Food and Beverage In-kind items and services $112.92 General
Category: HCV
03/28/2019 AbbVie, Inc. Mavyret (Drug) Food and Beverage In-kind items and services $117.84 General
Category: Virology
03/14/2019 Merck Sharp & Dohme Corporation ZINPLAVA (Biological) Food and Beverage In-kind items and services $123.04 General
Category: INFECTIOUS DISEASE
02/07/2019 Gilead Sciences, Inc. Epclusa (Drug) Food and Beverage In-kind items and services $125.00 General
Category: HCV
02/01/2019 Merck Sharp & Dohme Corporation DIFICID (Drug), ZINPLAVA Food and Beverage In-kind items and services $14.69 General
Category: INFECTIOUS DISEASE
01/31/2019 AbbVie, Inc. Mavyret (Drug) Food and Beverage In-kind items and services $144.34 General
Category: Virology
08/07/2018 Merck Sharp & Dohme Corporation DIFICID (Drug), ZINPLAVA Food and Beverage In-kind items and services $121.11 General
Category: INFECTIOUS DISEASE
06/19/2018 Gilead Sciences, Inc. Vemlidy (Drug) Food and Beverage In-kind items and services $124.98 General
Category: HBV
03/12/2018 Gilead Sciences, Inc. Epclusa (Drug) Food and Beverage In-kind items and services $125.00 General
Category: HCV
03/09/2018 GlaxoSmithKline, LLC. SHINGRIX (Biological) Food and Beverage In-kind items and services $123.95 General
Category: VACCINES
07/27/2017 Merck Sharp & Dohme Corporation DIFICID (Drug) Food and Beverage In-kind items and services $123.04 General
Category: INFECTIOUS DISEASE
02/28/2017 Gilead Sciences Inc Food and Beverage In-kind items and services $124.98 General
02/16/2017 AbbVie, Inc. Viekira (Drug) Food and Beverage In-kind items and services $134.80 General
Category: Virology

About Dr. Mark Siegel, M.D

Dr. Mark Siegel, M.D is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013981380.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Siegel, M.D has received a total of $2,468 in payments from pharmaceutical and medical device companies, with $131.00 received in 2023. These payments were reported across 21 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($2,468).

Practice Information

  • Specialty Gastroenterology
  • Location New York, NY
  • Active Since 02/14/2006
  • Last Updated 07/08/2007
  • Taxonomy Code 207RG0100X
  • Entity Type Individual
  • NPI Number 1013981380

Products in Payments

  • DIFICID (Drug) $401.75
  • Mavyret (Drug) $395.31
  • Epclusa (Drug) $362.92
  • SUCRAID (Drug) $299.99
  • ZINPLAVA (Biological) $248.04
  • Viekira (Drug) $134.80
  • ZEPOSIA (Drug) $131.00
  • Vemlidy (Drug) $124.98
  • SHINGRIX (Biological) $123.95
  • RELIZORB (Device) $119.93

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Gastroenterology Doctors in New York